BioNTech SE
PublicBioNTech SE is now publicly traded
The data on this page reflects BioNTech SE's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Oct 10, 2019
Last Round
Grant
May 20, 2025
Total Funding Raised
$1.87B
Company Overview
BioNTech SE is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
Sector
Healthcare
AI Layer
Application
Keywords
BioNTech SE Comparables
Compare BioNTech SE with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genevation LTD | 63% | |
| NeoCura Bio-Medical Technology Co., Ltd. | 60% | |
| ViferaXS GmbH | 60% |
BioNTech SE Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 20, 2025 | ||||
| Follow-on Offering | Jul 27, 2020 | ||||
| Debt | Jun 11, 2020 | ||||
| Debt | Dec 17, 2019 | ||||
| IPO | Oct 10, 2019 | ||||
Strategic | Aug 30, 2019 |
Key People
Founding team and executive leadership
BioNTech SE Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B, Series A |
| Janus Henderson Group | Series B, Series A |
| Temasek | Debt |
| MIG Capital | Seed |
| UK government | Grant |
| Bryan, Garnier & Co. | Follow-on Offering, IPO |
| Canaccord Genuity | Follow-on Offering, IPO |
BioNTech SE Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access